Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.22B P/E - EPS this Y 84.20% Ern Qtrly Grth -
Income -89.62M Forward P/E -19.08 EPS next Y -9.20% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg 15.00%
Dividend N/A Price/Book 5.16 EPS next 5Y - 52W High Chg -25.00%
Recommedations 1.60 Quick Ratio 18.89 Shares Outstanding 46.62M 52W Low Chg 53.00%
Insider Own - ROA -22.16% Shares Float 115.22M Beta -
Inst Own 94.91% ROE -33.33% Shares Shorted/Prior 4.11M/3.24M Price 31.86
Gross Margin - Profit Margin - Avg. Volume 205,693 Target Price 80.50
Oper. Margin - Earnings Date - Volume 1,808,564 Change -12.52%
About Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Structure Therapeutics Inc. News
04/24/24 3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains
03/30/24 7 Small-Cap Stocks that Wall Street Loves for Good Reason
03/10/24 We Think Structure Therapeutics (NASDAQ:GPCR) Can Afford To Drive Business Growth
03/08/24 Structure Therapeutics to Present at Leerink Partners Global Biopharma Conference
03/08/24 Structure Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Highlights
01/22/24 Here’s Why Structure Therapeutics (GPCR) Fell in Q4
12/25/23 Structure Therapeutics Stock Just Crashed. Here's Why It Could Be Worth Buying Now
12/18/23 Structure Plummets 43% After Trailing Lilly In Obesity Treatment
12/18/23 Structure Therapeutics Provides Comprehensive GSBR-1290 Program Update Including Clinically Meaningful Proof-of-Concept Data From Phase 2a Clinical Study
12/18/23 Structure Therapeutic obesity pill shows promise in mid-stage trial
12/18/23 Structure shares sink as obesity pill misses expectations in small study
12/11/23 3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023
11/29/23 If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
11/29/23 11 Best Young Stocks to Buy and Hold For 20 Years
11/27/23 11 Best Upside Stocks To Buy Right Now
11/26/23 2 Biotech Stocks That Could Soar in December
11/14/23 Structure Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights
11/03/23 Should You Still Buy the Nasdaq's Best-Performing October Stocks?
10/06/23 Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
10/02/23 Why Shares of Structure Therapeutics Are Up Monday
GPCR Chatroom

User Image DAR2487 Posted - 04/30/24

$GPCR trading higher from Eli lily? Hmm

User Image Justy_Nuff Posted - 04/30/24

$GPCR what happened????

User Image Quantumup Posted - 04/23/24

BMO $GPCR OP/$83 Oral GLP-1RAs will be the next leap4ward4metabolic med. A "homerun" (26% wt loss) could renew inv zeal, shrs currently reflect a less conclusive readout (5-6% wt loss), considered fixable w/ optimal dosing; incremental updates, T2D validation make⬇️side unlikely: $vktx $lly $nvo

User Image biolover Posted - 04/21/24

$ALT $GPCR $LLY $NVO $VKTX all these drugs are known and of no competition to Viking drug. Not the sc nor the po

User Image RonIsWrong Posted - 04/21/24

13 new obesity drugs could hit the market by 2029 amid surging demand $LLY $NVO [...] Beginning in 2024, the number of obesity drug launches is expected to climb significantly, reaching a peak of four launches per year in 2027 and 2028. [...] Other drug candidates in mid-stage development for obesity include Viking Therapeutics’ ($VKTX) VK2735, Structure Therapeutics’ ($GPCR) GSBR-1290 and Altimmune’s ($ALT) pemvidutide, Pfizer’s (PFE) danuglipron, and Amgen’s (AMGN) AMG133, also known as MariTide.

User Image NoFearHere Posted - 04/18/24

$GPCR it's back in the buy Zone this line is held it so far

User Image BioRich Posted - 04/15/24

$TERN Phase 1 Readout for TERN-601 and TERN-701 expected in 2H24. Preliminary information shared in last earnings call/presentation shows extremely optimistic outcomes. Strong balance sheet with cash on hand to fund through 2025. Added a new CBO (Chief Business Officer) that led $GPCR Structure Therapeutics to a success IPO and served as Senior VP and Head of Business Development for monster $SGMO where she secured licensing agreements with major market players with the potential value in excess of 6$ billion. The presentation slides show how initial data compares to $ALT and $VKTX and was insanely impressive. I'll post when I find. Not a pump, I believe this is a lottery ticket at these prices and it's potential.

User Image RickiWins Posted - 04/10/24

$TERN $GPCR was her former company, peep the value

User Image BullYa Posted - 04/09/24

$GPCR ridiculous! Buy the dip with $3.40 discount per share, that’s a good deal of the day.

User Image Justy_Nuff Posted - 04/05/24

$GPCR gpcr let's gooooo

User Image CDMO Posted - 04/02/24

$GPCR got stopped out today, 4% loss

User Image OMillionaires Posted - 03/25/24

lets go $GPCR back over $45 plz

User Image Rkramden60 Posted - 03/22/24

$GPCR I own a ton of this but you take a close look at $LENZ looks very promising!! My two cents

User Image Stayfocused489 Posted - 03/21/24

$GPCR Even with help they are a long shot. $VKTX as well another long shot.

User Image Stayfocused489 Posted - 03/21/24

$GPCR Doesn’t this do the same As the other ones? GLP-1 Inhibitor being the main source. Who would take this on. Phizer? Doing DD.

User Image Stayfocused489 Posted - 03/21/24

$GPCR Bullish on a temporary pull back.

User Image ExcelsiorTrading Posted - 03/21/24

$GPCR what a beast

User Image Rkramden60 Posted - 03/21/24

$GPCR does anyone think a partnership or buyout is possible soon!!!

User Image OMillionaires Posted - 03/21/24

3rd time a charm at $50 for $GPCR ?

User Image OMillionaires Posted - 03/21/24

In more $GPCR calls

User Image NoFearHere Posted - 03/21/24

$GPCR there it is>..BREAKOUT!

User Image Student_ Posted - 03/21/24

$GPCR I don’t understand why Structure is up, given the data was lackluster. I realize it’s a big market, but what niche will this have as an inferior product to Lilly or now, possibly NVO’s oral.

User Image Axadude Posted - 03/20/24

$GPCR $VKTX Neither have that money ain’t happening

User Image NoFearHere Posted - 03/20/24

$GPCR this stock is another room that sleeps even when it's rising it's unknown I suppose I can't couldn't have blocked everybody in here🤣🤣🤣

User Image NoFearHere Posted - 03/20/24

$GPCR that macd's just now curling up there's inside or buys going on after hours it's Prime to break out above that $48 and run into the 50s watching closely for a swing trade opportunity

User Image NoFearHere Posted - 03/20/24

$GPCR above $43 which clears the 50 and 200 dma this thing has a clear sky to 48 dollars along with what's going on with these form Four A's filed after hours it could have a run

User Image NoFearHere Posted - 03/20/24

$GPCR a lot of fours being filed after hours that's a bullish sign

User Image BTECHINV Posted - 03/20/24

Per today's BMO Summit, projected future GLP-1 TAM estimates rising well north of $100 B+, global map from today's Economist newsletter (picture worth a thousand words). The medical aspects of Obesity are coming into focus in potential Gen-3 drugs, playing to Pemvidutide's unique strengths as a single drug candidate that cuts across the four major domains of Liver Fat, Cardiometabolic, Obesity (WL sustainability) and safety. Best wishes to all, future is bright for emerging leaders (imo): $ALT, $VKTX, $MDGL, $GPCR Disclosure: Long Altimmune (Pemvidutide, GCGR/GLP-1), not medical advice, not investment advice.

User Image Crackjack Posted - 03/20/24

$GPCR $VKTX shhhh. Steve, we had decided not to disclose in public forums…

User Image bioanticipation Posted - 03/20/24

$VKTX don’t shoot the messenger but wisdom tells me that Viking probably announces a buyout tomorrow at $140. $13.5B all cash probably Merck or Pfizer. The option chain doesn’t run the way it has on a data play. It has buyout written all over it. In fact based on all available evidence there is no way the oral has a home run enough to catapult this as much as the options suggesting. $gpcr running after hours too as that’s a good proxy way to play Viking buyout. (I know Cnbc mention but it wasn’t anything that should lead to a 10% move)

Analyst Ratings
Cantor Fitzgerald Overweight Apr 18, 24
Cantor Fitzgerald Overweight Apr 9, 24
JMP Securities Market Outperform Mar 8, 24
JMP Securities Market Outperform Nov 20, 23
JMP Securities Market Outperform Nov 15, 23
Piper Sandler Overweight Oct 27, 23
Piper Sandler Overweight Oct 26, 23
JMP Securities Market Outperform Oct 19, 23
BMO Capital Outperform Oct 3, 23